Filoviridae infectious disease

This study tested a new vaccine designed to protect against Sudan ebolavirus, a close relative of the Ebola virus. Researchers gave the vaccine or a placebo to 125 healthy adults to see if it is safe and triggers an immune response. The goal is to find a way to prevent this deadl…

This study tested an experimental Ebola vaccine (V920) in 251 HIV-infected adults and adolescents to see if it is safe and triggers an immune response. Participants received either the vaccine or a placebo, and researchers monitored side effects and antibody levels. The trial too…

This early-stage trial tested a new vaccine called PHV01 against Marburg virus, a rare but severe disease. 36 healthy adults received either the vaccine or a placebo to check safety and immune response. The study aims to find a safe dose and see if the vaccine triggers antibodies…

This completed Phase 2 trial tested the antiviral drug favipiravir in 126 people with Ebola in Guinea. The goal was to see if it could reduce deaths. Participants received high doses of the drug by mouth for up to 10 days. The study aimed to find a practical treatment for Ebola, …

This study looked at whether giving hospital-level care to acutely ill adults in their own homes in rural areas works well. 160 people with various conditions like infections, heart failure, or COPD took part. The goal was to see if this approach could lower costs and help patien…

This study looked at how well a new, quick finger-prick test (LumiraDx CRP) measures CRP levels compared to a standard lab test. CRP is a marker of infection, inflammation, or tissue injury. 79 adults with symptoms of these conditions took part. The goal was to see if the new tes…

This early study tested whether a special PET scan using a radioactive form of vitamin B9 (11C-PABA) can help doctors see infections deep inside the body. Researchers scanned 13 healthy people and patients with known or suspected infections. The goal was to see if this method can…

This study tested whether a booster dose of the Ebola vaccine (V920) could improve and extend immune protection in 248 healthy adults at risk of Ebola exposure through their jobs. Participants received the primary vaccine and were randomly assigned 18 months later to get a booste…

This study looked at children who survived Ebola and compared them to close contacts who never got sick. Researchers checked for brain, nerve, and thinking problems more than 5 years after infection. The goal was to understand what lasting issues survivors face, not to test a tre…

This study looked at 156 critically ill patients to find out what factors help achieve the right levels of beta-lactam antibiotics in the blood. Researchers collected clinical data and used therapeutic drug monitoring to see which patients reached target concentrations. The goal …

This completed study in the Democratic Republic of the Congo followed 787 people who survived Ebola and their close contacts. Researchers tracked their health over time, looking for lingering virus, immune responses, and other infections. The goal was to better understand the lon…